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2Abstract
Background: Vagus nerve stimulation (VNS) is currently used to treat refractory
epilepsy and is being investigated as a potential therapy for a range of conditions,
including heart failure, tinnitus, obesity and Alzheimer’s disease. However, the
invasive nature and expense limits the use of VNS in patient populations and hinders
the exploration of the mechanisms involved.
Objective: We investigated a non-invasive method of VNS through electrical
stimulation of the auricular branch of the vagus nerve distributed to the skin of the
ear – transcutaneous VNS (tVNS) and measured the autonomic effects.
Methods: The effects of tVNS parameters on autonomic function in 48 healthy
participants were investigated using heart rate variability (HRV) and
microneurography. tVNS was performed using a transcutaneous electrical nerve
stimulation (TENS) machine and modified surface electrodes. Participants visited the
laboratory once and received either active (200 µs, 30Hz; n = 34) or sham (n = 14)
stimulation.
Results: Active tVNS significantly increased HRV in healthy particpants (p = 0.026)
indicating a shift in cardiac autonomic function towards parasympathetic
predominance. Microneurographic recordings revealed a significant decrease in
frequency (p = 0.0001) and incidence (p = 0.0002) of muscle sympathetic nerve
activity during tVNS.
Conclusion: tVNS can increase HRV and reduce sympathetic nerve outflow, which
is desirable in conditions characterised by enhanced sympathetic nerve activity, such
as heart failure. tVNS can therefore influence human physiology and provide a
simple and inexpensive alternative to invasive VNS.
Key words: vagus nerve stimulation, sympathetic nervous system, neuromodulation
3Abbreviations List: ABVN – auricular branch of the vagus nerve; HF – high
frequency; HRV – heart rate variability; LF – low frequency; MSNA – muscle
sympathetic nerve activity; TENS – transcutaneous electrical nerve stimulation; tVNS
– transcutaneous vagus nerve stimulation; VNS – vagus nerve stimulation.
4Introduction
Electrical stimulation of the cervical vagus nerve has been approved for
treatment resistant epilepsy in Europe and the USA for over 15 years and has been
used to treat over 50,000 epilepsy patients (1). VNS is also an approved therapy for
treatment resistant depression in the USA (2) and has been investigated as a
potential therapy for a wide range of conditions including heart failure (3),
inflammation (4), Alzheimer’s disease (5), obesity (6), chronic pain (7) and tinnitus
(8). However, despite positive indications from pilot studies larger scale trials are
rarer. For example, even though the cognitive function of 70% of patients with
Alzheimer’s disease improved or did not decline during a 1 year pilot study (5), no
larger scale trials have been reported.
One factor that may hinder larger trials of VNS is the invasive nature of VNS.
VNS requires surgical implantation of a bipolar electrode around the cervical vagus
nerve and implantation of a generator subcutaneously in the thoracic wall. This is
associated with technical and surgical complications including wound infection,
cardiac arrhythmia under test stimulation and electrode malfunction (9). In addition,
side effects include hoarseness, dysphagia, cough and pain (10).
Given the number of conditions that VNS has the potential to benefit, a
simpler, less invasive approach would enable treatment of significantly larger
numbers. A potential non-invasive route for VNS is electrical stimulation of the
auricular branch of the vagus nerve (ABVN), which is distributed to the external ear
(Figure 1) (11). This stimulation can be performed transcutaneously by applying
surface electrodes or acupuncture needles to the external ear (tVNS). Such tVNS
has been trialled in patients with coronary artery disease (12, 13), epilepsy (14) and
chronic pain (15), however, the outcomes investigated are varied and mostly
5subjective. In addition, the stimulation parameters used differ widely, therefore, little
is known about the optimal parameters for tVNS.
VNS has proven effective in pilot studies for the treatment of heart failure (16),
for which a multi-centre trial is on-going (ClinicalTrials.gov Identifier: NCT01303718).
Approximately 5.7 million people in the US have heart failure (17) costing the US
economy $34.4 billion every year (18). Heart failure is a leading cause of mortality
and it is estimated that 50% of people die within 5 years of diagnosis. Heart failure is
characterised by decreased parasympathetic and increased sympathetic nerve
activity (19). Therefore, if tVNS can be shown to influence this autonomic balance
towards parasympathetic predominance it could provide a method to correct
imbalance in heart failure patients.
In this study we investigated the effects of tVNS on cardiovascular autonomic
function in healthy participants by measuring heart rate variability. We then applied
microneurography to record muscle sympathetic nerve activity directly during tVNS.
6Methods
General Protocol
The study was approved by the University of Leeds Ethics Committee and
conducted in accordance with the Declaration of Helsinki. Informed written consent
was obtained from all participants. 48 healthy participants (24female, 24 male; 20-62
years old) were recruited for the study. Inclusion criteria were male or female over
the age of 18 years. Exclusion criteria were a history of cardiovascular disease,
diabetes or hypertension. The study began between 8-10am in a dedicated study
room at 21 ± 2°C. All participants were asked to avoid alcohol and intense exercise
12 hours prior to attendance. They were also asked to avoid caffeine and nicotine on
the morning of the study and to void their bladder before the study commenced.
Participants were asked to lie on a couch in a semi-supine position while heart rate,
blood pressure and respiration were monitored continuously. Data were recorded at
baseline, during tVNS and during recovery and each recording period lasted
15minutes. All participants visited the laboratory once and received either active or
sham transcutaneous vagus nerve stimulation (tVNS).
Transcutaneous Vagus Nerve Stimulation (tVNS)
tVNS was performed using a Transcutaneous Electrical Nerve Stimulation (TENS)
device (V-TENS Plus, Body Clock Health Care Ltd, UK) with modified surface
electrodes. Electrodes were placed on the inner and outer surface of the tragus of
the ear. Active tVNS (n = 34) was applied continuously for 15 minutes with a pulse
width of 200 µs and pulse frequency of 30 Hz. Amplitude was adjusted to the level of
sensory threshold (10-50 mA). Sham tVNS (n = 14) was performed by placing the
electrodes on the tragus and increasing amplitude until the participant reported
7feeling sensation. Participants were then told that the amplitude would be reduced
slightly to prevent discomfort but the electrode leads were disconnected from the
TENS machine without the participants’ knowledge.
Heart Rate Variability (HRV)
A three lead ECG was used to monitor and record heart rate. Electrodes (Ambu, UK)
were placed on left and right clavicles and costal margins. This arrangement enabled
changing electrode polarities to select the lead that detected the most prominent R
peak for subsequent HRV analysis (normally lead II). HRV was analysed offline
using LabVIEW software (National Instruments, USA). A threshold was set to detect
R peaks from an 8 minute ECG recording and R-R intervals used to produce a
tachogram. The ECG was inspected to ensure all R peaks were detected and there
were no abnormalities in the ECG such as ectopic beats (e.g. premature ventricular
complexes). Ectopic beats could be corrected using a linear spline to average the R-
R interval prior to and following the ectopic. If more than 2 ectopics were detected
the recording was excluded. The resulting tachogram underwent 512 point Fast
Fourier Transform with a Hanning window to calculate the power spectrum of HRV
with the low frequency (LF) component at 0.04-0.15 Hz and the high frequency (HF)
component at 0.15-0.40 Hz. LF and HF power were also converted to normalised
units as a percentage of the total power to determine LF/HF ratio. The HF
component reflects parasympathetic modulation of heart rate (20) and the LF
component reflects both sympathetic and parasympathetic modulation of heart rate
(21). The ratio of low frequency (LF) and high frequency (HF) oscillations of heart
rate variability can be used as an index of cardiac autonomic balance such that a
decrease in LF/HF ratio indicates a shift in cardiac autonomic balance towards
8parasympathetic predominance and thus an improvement in HRV (20, 22). It is
important to note that this may be due to either a decrease in sympathetic activity or
an increase in parasympathetic activity.
Respiration
A piezo-electric transducer (Pneumotrace, UFI, USA) was placed round the thorax to
monitor and record respiration rate. A respiration rate <10 breaths/min was
unacceptable for HRV analysis as the HF component is respiration dependent. At
slow respiration rates the HF peak of the HRV spectrum can merge with the LF peak
(23). In this case the subjects were asked to use a breathing metronome set at 16
breaths/min (n = 3).
Microneurography
Muscle sympathetic nerve activity (MSNA) was recorded as previously described
(24-26) in 10 volunteers receiving active tVNS (8 male, 2 female; 29-59 years). Two
tungsten microelectrodes were inserted percutaneously below the knee. One
electrode was inserted into the peroneal nerve (recording electrode) and the second
was inserted into subcutaneous tissue 1-2cm away (reference electrode). The raw
nerve signal was amplified (x50k), filtered (0.7-2 kHz; Neurolog) and digitised (16
kHz; Power 1401, CED). The data was displayed in real time and recorded on a PC
(Dell laptop) using Spike2 (version 7; CED). This allowed inspection of the nerve
signal during the experiment. The recording microelectrode was manipulated until a
single unit could be visualised. To confirm that this was a sympathetic
vasoconstrictor unit the following conditions were met; 1) the unit occurred in
diastole, 2) there was no increase in activity in response to brushing the skin of the
9leg, 3) activity increased in response to cold presser test or isometric handgrip test
(Fig. 4a). Cold presser test comprised placing one hand in ice water (approximately
4°C) for one minute. Isometric handgrip test involved squeezing a handgrip at 50%
maximal voluntary contraction for 2 minutes. Further confirmation was obtained
during off-line analysis by superimposing all putative MSNA units to ensure the
amplitude and shape remained constant indicating that these were recorded from the
same axon (Figure. 4B,C). MSNA bursts were also inspected by rectifying and
integrating (time constant 0.1s) the neurogram. MSNA single unit frequency (per
min) was calculated. MSNA single unit incidence (per 100 heart beats) were also
calculated to limit the effect of any changes in heart rate. Data were normalised to
baseline due to a high degree of inter-individual variation.
Data Acquisition
ECG, MSNA, blood pressure and respiration data were split into two channels and
fed into two data amplification systems (Coulbourn Lab Sinc V, Coulbourn Ltd, USA
and Neurolog, CED, UK). Channels were independently calibrated before digitisation
and storage on PCs. Data channels were then displayed on monitors using
LabVIEW (National Instruments, USA) and Spike2 (CED, UK) software. The data
were sampled at 12-16 kHz and stored on hard drives.
Statistical analysis
All statistical analyses were carried out using SPSS (version 18). Independent t-tests
or Mann-Whitney U test were used to compare group characteristics. Repeated
measures ANOVA was used to analyse time effect (baseline, stimulation, recovery)
in each group alone with post hoc Bonferroni correction. To analyse the effects of
10
active and sham tVNS, a mixed mode ANOVA with group (active or sham
stimulation) and time (baseline,,stimulation, recovery) was used. . Where interactions
were revealed, post hoc analyses were undertaken using repeated measures
ANOVA on each group separately. The Greenhouse – Geisser correction was used
where data did not meet sphericity. Linear regression was used to explore the
relationship between variables. Data are presented as group mean ± standard error
of the mean (S.E.M.) unless stated otherwise. A 2-tailed probability value < 0.05 was
considered statistically significant.
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Results
tVNS significantly alters heart rate variability
Baseline characteristics of the active and sham tVNS groups were not significantly
different (Mann-Whitney U test, p > 0.05; Table 1).
Repeated measure ANOVA revealed a significant decrease in LF/HF ratio during
active tVNS (time effect, p = 0.026; Table 2; Figure 2). There was no significant
change in LF/HF ratio in the sham group (p > 0.05). There was a modest but
significant decrease in heart rate (p < 0.005) during active and sham tVNS. There
was also a significant increase in mean BP (p < 0.005) during active and sham tVNS
that did not recover. This finding is likely to be due to the method of measurement
(Finometer) as there was no significant change in BP measurements taken using an
arm sphygmomanometer (see Supplementary Figure 2) whereas the increase in BP
measured using the Finometer persisted into the recovery period suggesting that the
increase may be due to constriction and oedema in the finger (27).
Response to tVNS is correlated with baseline LF/HF ratio
Linear regression revealed a relationship between baseline LF/HF ratio and the
change in LF/HF ratio during tVNS such that a higher LF/HF ratio predicts a greater
response to tVNS (R2 = 0.58; p < 0.0005; Figure 3A). Higher baseline LF/HF values
were also observed with increasing age (R2 = 0.19; p = 0.013; Figure 3B).
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tVNS reduces muscle sympathetic nerve activity
Applying microneurography to directly record sympathetic vasoconstrictor nerve. a
significant decrease in MSNA frequency (time effect, p = 0.001) and incidence (time
effect, p = 0.002; Figure 4) was detected during tVNS (n=10). Eight of these 10
participants responded to tVNS with a decrease in MSNA, whilst the remaining 2
showed no change, which corresponded with the effects of tVNS on HRV on these
individuals (Supplementary Figure 3). These participants did not differ in baseline
characteristics (age, BMI, heart rate, blood pressure etc) from the rest of the tVNS
group or sham groups (Kruskal-Wallis test, p > 0.05).
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Discussion
This study shows that transcutaneous vagus nerve stimulation (tVNS) can alter
cardiovascular autonomic control in healthy humans and highlights the role of the
sympathetic nervous system in mediating tVNS effects. tVNS significantly decreased
LF/HF ratio, indicating improved heart rate variability with a shift in cardiac
autonomic balance towards parasympathetic/vagal dominance. This shift occurred
alongside a decrease in MSNA, revealed by microneurography during tVNS.
tVNS effects on cardiovascular autonomic function
Increased sympathetic activity and/or reduced parasympathetic nerve activity as
indicated by HRV is not only a powerful and independent predictor of poor prognosis
in patients with cardiovascular disease (28, 29), but also a risk factor for mortality in
healthy populations (30). Similarly, increased MSNA is associated with poor
prognosis in heart failure and is also elevated in hypertension, obstructive sleep
apnoea and obesity (31). The ability to favourably alter HRV and MSNA through
tVNS in a healthy population is significant and could be applied to many populations
where cardiovascular autonomic balance is shifted toward sympathetic
predominance e.g. older or sedentary (32) populations or in conditions with
sympathoexcitation such as heart failure (33). Indeed, the significant correlation
between baseline LF/HF ratio and the change in LF/HF ratio during stimulation
implies that tVNS may be even more effective in these populations compared to the
healthy population used in this study.
Of particular interest in this study is the finding that the LF/HF ratio and MSNA
remain lower than baseline levels during the recovery period after tVNS has ceased.
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The stimulation and recovery period lasted 15 minutes therefore the long term
effects of tVNS on cardiovascular autonomic control require further investigation,
however, HRV effects of tVNS performed using acupuncture increased in HF power
(indicating increased parasympathetic activity) for at least an hour after stimulation
had ceased (34). The increase in HF power reported by this study is contrary to our
findings. This may be due to the smaller sample size used (n = 12), the different
tVNS technique used or the limitation of HRV analysis as an indirect measure of
cardiac autonomic activity. La Marca et al. (35) demonstrated that auricular
electroacupuncture increases respiratory sinus arrhythmia (RSA, mediated by the
vagus nerve) in healthy participants (n = 14) suggesting increased vagal activity,
however, this is also an indirect measure of parasympathetic activity. One of the
limitations of these studies, including ours, is that they have all used healthy
participants. The extent of the tVNS effects that might be observed in patient,
sedentary or older populations which characteristically have reduced
parasympathetic activity therefore seems likely to be underestimated.
The first clinical study of tVNS found that electroacupuncture of both ears was
beneficial for patients with coronary artery disease (12, 13). Patients (n = 10)
received tVNS for 15mins/day for 10 consecutive days. After 4 treatments, angina
symptoms at rest were abolished and patients no longer required vasodilators. After
7 treatments, patients had improved exercise tolerance and were able to climb 5-7
flights of stairs without developing angina symptoms. These studies also reported
that the improvement in angina symptoms persisted after the cessation of tVNS
treatment for up to 3 weeks. Recently, tVNS using surface electrodes has been
investigated as a possible analgesic (15, 36) and has also been trialled as an
15
alternative to invasive cervical VNS in patients with refractory epilepsy (14). These
studies also monitored heart rate and blood pressure and reported no significant
changes. Napadow et al. (15) also analysed ECG data for HRV and found tVNS had
no significant effect (n = 10).These findings are contrary to the results of our study,
however this seems likely to be due to the smaller sample sizes and the different
stimulation parameters used.
Potential pathways of tVNS cardiovascular autonomic effects
The neurocircuitry underlying tVNS autonomic effects requires further elucidation.
The auricular branch of the vagus nerve has previously received little attention and
hence there is a dearth of information regarding its central projections and its
peripheral distribution. Only one study in the literature investigates the distribution of
the ABVN to the external ear (11). This reports that the ABVN is distributed to the
tragus, concha, cymba concha and anti-helix of the ear. EEG studies have shown
that tVNS of the tragus elicits vagus somatosensory evoked potentials (VSEP) (37,
38). Interestingly, stimulation at other sites in the ear not supplied by the ABVN
(helix, anti-helix, scapha and lobe) did not elicit VSEPs supporting evidence that the
tragus is innervated by the ABVN. Functional MRI of tVNS of the tragus in humans
revealed a similar activation pattern to conventional cervical VNS further supporting
the potential of tVNS at the tragus as a non-invasive alternative (39).
The central projections of the ABVN have been investigated in cats and dogs and
were found to project to the nucleus tractus solitarius (NTS), which plays an integral
role in relaying vagal afferent visceral information (40, 41). In addition, neuronal
tracing from the junction of the concha and external auditory meatus in rats revealed
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sensory afferent terminations in the NTS and dorsomedial spinal trigeminal tract
(42). Indeed, the ABVN is thought to be involved in some peculiar somatovisceral
reflexes. These include the ear-cough reflex (Arnold’s reflex), estimated to be
present in approximately 4% of the general population (43), whereby stimulation of
the external auditory meatus (e.g. syringing) mimics the cough response mediated
by vagal afferent innervation of the trachea. Other examples include the ear-gag
reflex, ear-lacrimal reflex and auricular syncope (43, 44) although these are rare.
Another interesting phenomenon involving the ABVN is pain referred to the external
ear from viscera supplied by the vagus nerve in conditions such as lung cancer (45-
47), gastroeosophageal reflux (48) and myocardial infarction (49, 50). Furthermore,
cervical vagus nerve stimulation has also been reported to cause ear pain (16, 51).
Based on the results of this study, the proposed pathway of tVNS autonomic effects
could involve activation of the NTS by ABVN afferents. This could activate the caudal
ventrolateral medulla to inhibit the rostral ventrolateral medulla and thus reduce
sympathetic output (52). In addition, the NTS could also activate the dorsal motor
nucleus of the vagus and the nucleus ambiguus to increase parasympathetic activity
(53). However, the effects of tVNS on parasympathetic activity are unclear.
Scope of tVNS therapy for cardiovascular diseases
VNS is already being trialled as a potential heart failure therapy and has resulted in
positive clinical outcomes (3). Our findings support the use of tVNS as a non-
invasive method of VNS for cardiovascular diseases. Of particular interest is the
finding that tVNS reduces sympathetic outflow. Sympathoexcitation is the hallmark of
many conditions including heart failure, hypertension and obstructive sleep apnoea
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(31). Further, auricular electroacupuncture has beneficial effects in coronary artery
disease (12, 13). The tVNS approach described here may therefore offer a simple,
non-invasive and economical alternative that could make vagus nerve stimulation a
widely available therapy and potentially improve quality of life for patients with a
broad range of cardiovascular diseases.
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Figure Legends
Figure 1. The distribution of the auricular branch of the vagus nerve to the external
ear (shaded area, extrapolated from Peuker and Filler(11)). C, concha; T, tragus;
CyC, cymba concha.
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Figure 2 There is a significant decrease in LF/HF ratio during active tVNS (p =
0.026) whereas there is no significant change during sham tVNS.
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Figure 3. There is a relationship between baseline LF/HF ratio and change in LF/HF
ratio during tVNS indicating that higher LF/HF ratios predict a greater decrease in
LF/HF during tVNS (R2=0.58; p<0.0005; A). There is a relationship between age and
baseline LF/HF ratio (R2=0.19; p=0.013; B).
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Figure 4 Example microneurography recording during baseline (A) and during tVNS
(B) indicating electrocardiogram (ECG), blood pressure (BP) and MSNA. MSNA
units in more detail (C) and overlaid (D). tVNS significantly reduces MSNA frequency
(E; *P = 0.0001) and incidence (F; *P = 0.0002; normalized data; n = 10).
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Sham Active
Number 14 (6 Ƃƃ 34 (18 Ƃƃ
Age (years) 38 ± 3.48 34 ± 2.3
BMI
(kg/m2)
23.9 ± 0.67 24.9 ± 0.71
Heart rate
(bpm)
64 ± 2.49 64 ± 1.31
Mean BP
(mmHg)
79 ± 3.59 83 ± 1.99
Table 1 Baseline characteristics. There was no significant difference in baseline
characteristics between active and sham tVNS groups.
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Table 2 Heart rate variability values for sham and active tVNS groups There
was a significant decrease in LF/HF ratio during active tVNS (p = 0.026). There was
no significant (n.s.) change in total power, low power or high power during active
tVNS. There was no significant change in any HRV values in the sham tVNS group.
Base Stimultion p Base Stimulation p
Total
power
(ms2)
2463.75
±732.50
2789.22
±843.02
n.s. 2735.31
±422.23
3212.17
±497.45
n.s.
LF
Power
(ms2)
615.52
±168.65
664.63
±160.85
n.s. 906.39
±133.74
821.49
±177.62
n.s.
HF
Power
(ms2)
1109.41
±395.90
1286.40
±469.05
n.s. 972.67
±208.32
1043.02
±178.65
n.s.
LF/HF 1.16
±0.30
1.19
±0.32
n.s. 1.26
±0.15
1.04
±0.14
0.026
Sham tVNS Active tVNS
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Supplementary Data
Electrode positioning for tVNS
Before undertaking the main study presented in this paper, pilot studies were performed to
refine the tVNS methodology. Since the auricular branch of the vagus nerve is distributed to
parts of the external ear including the tragus, concha and cymba concha 1 (Figure.1), the
effect of stimulating these three areas by specific electrode placement at the ear was
investigated.
Methods
To determine an effective electrode configuration three different electrode configurations
were investigated in 63 healthy volunteers (34 female, 29 male; 20-66 years old); tragus,
tragus + cymba or concha. The efficacy of tVNS of either the right ear only or both ears
simultaneously was also investigated in the same participants (Supplementary Table 1).
tVNS was performed continuously for 15 minutes with a pulse width of 20 µs and pulse
frequency of 15 Hz. Amplitude was adjusted to the level of sensory threshold (10-50 mA).
Data were recorded for 15 minutes at baseline, during tVNS and recovery period.
Right side only Left and right sides
Tragus Cymba +
Tragus
Concha Tragus Cymba +
tragus
Concha
10 8 3 24 11 7
Supplementary Table 1 Number of participants in each electrode configuration group
To analyse the effects of different electrode configurations, mixed mode ANOVA with group
(electrode configuration) and time (baseline, stimulation, recovery) was used. Where
interactions were revealed, post hoc analyses were undertaken using repeated measures
ANOVA on each group separately. The Greenhouse – Geisser correction was used where
data did not meet sphericity.
Results
There was no significant change in HRV during tVNS when data from all participants were
analysed (repeated measures ANOVA; Supplementary Table 3). However, HRV analysis
indicated that there were responders (those who had a decrease in LF/HF ratio during tVNS;
n = 31) and non-responders (n = 32). Baseline LF/HF ratio was significantly higher in
responders compared to non-responders (LF/HF ratio 1.32 and 1.04 respectively; p = 0.038;
Supplementary Table 2). Comparing the two groups revealed no significant differences in
other baseline characteristics such as body mass index (BMI), age, resting heart rate and
blood pressure (Mann-Whitney U test, Supplementary Table 2).
To determine if there were differences between the responder and non-responder groups
during tVNS a mixed mode ANOVA was performed to analyse the interaction between group
and stimulation. There was a significant interaction between group and time (p < 0.0005). To
understand the factors underlying this significance, further analysis of the responder group
alone revealed a significant decrease in LF/HF ratio (time effect, p < 0.0005; repeated
measures ANOVA; Supplementary Table 3) during tVNS indicating a shift in autonomic
balance towards parasympathetic predominance. Conversely, there was a significant
increase in LF/HF ratio in the non-responder group (time effect, p < 0.0005; Supplementary
Table 3) indicating that the interaction was due to an increase in LF/HF ratio in the non-
responder group compared to a decrease in the responder group. These experiments
indicated that tVNS effectively decreased the LF/HF ratio in a subset of participants.
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tVNS tVNS
responder
tVNS non-
responder
Number 63 (34 Ƃ
ƃ
31 (16 Ƃ
ƃ
32 (18 Ƃ
ƃ
Age (years) 38±1.66 38±2.39 37±2.35
BMI
(kg/m2)
24.5±0.57 24.2±0.54 24.8±1.00
Heart rate
(bpm)
65±1.16 63±1.79 66±1.48
Mean BP
(mmHg)
80±1.46 80±2.17 81±2.00
LF/HF 1.18±0.11 1.32±0.15* 1.04±0.15*,
Supplementary Table 2: Baseline characteristics There was a significant difference in
baseline LF/HF ratio between responders and non-responders (*p = 0.038). There was no
significant difference in other baseline characteristics.
Using the responder subset of participants alone the effect of electrode configuration was
investigated. A mixed mode ANOVA revealed no impact of electrode configuration on LF/HF
ratio (main effect for electrode configuration, p > 0.05). This suggests that the electrode
configuration did not influence the effectiveness of tVNS in reducing LF/HF in the responder
group. Due to ease of application tVNS of the tragus of both left and right ears was used for
all subsequent investigations.
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Base Stim p Base Stim p Base Stim p
Total
Power
(ms2)
2072.56
±291.50
2033.08
±343.28
ns 1953.7
±345.9
2041.1
±298.3
ns 2187.7
±340.4
2025.3
±293.6
ns
LF
Power
(ms2)
578.83
±92.29
588.49
±81.16
ns 623.0
±94.8
567.4
±93.4
ns 536.0±
93.3
608.9
±91.9
ns
HF
Power
(ms2)
823.99
±143.75
779.12
±123.28
ns 596.4
±210.3
761.2
±163.3
ns 1044.5
±206.9
796.5
±160.7
ns
LF/HF 1.18
±0.11
1.16
±0.10
ns 1.32
±0.15
0.95
±0.15
<0.0005 1.04
±0.15
1.35
±0.14
<0.0005
Supplementary Table 3: Heart rate variability values for L-tVNS responders and non-responder groups. There is a significant increase in
LF/HF ratio during stimulation in the responder group (p < 0.0005) and a significant increase in LF/HF ratio in the non-responder group (p <
0.0005).
Responders (n = 31) Non-responders (n = 32)Total group (n = 63)
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Stimulation Parameters for tVNS
The stimulation parameters (20 µs pulse width at 15 Hz) used in the initial study
investigating electrode configuration reduced LF/HF ratio in 49% healthy participants (n =
31/63). In order to improve the efficacy of tVNS, the effects of increasing pulse width to 200
µs and pulse frequency to 30 Hz were investigated in 34 healthy participants. The results of
these experiments are presented in the main text, however, here we compare the effects of
the original low pulse width and frequency (L-tVNS; 20 µs at 30 Hz; n = 63) stimulation with
the final high pulse width and frequency parameters (H-tVNS; 200 µs at 30 Hz) used in the
main study. In addition, sham stimulation (electrodes placed on the ear but no electrical
stimulation used) was also investigated in 14 healthy participants. There were no significant
differences in baseline characteristics between L-tVNS, H-tVNS and sham groups (including
BMI, age, sex, baseline heart rate, BP or LF/HF ratio; Kruskal-Wallis test, p > 0.05).
Increase pulse width and pulse frequency (H-tVNS) is more effective in altering
cardiovascular autonomic function
There was a significant interaction between stimulation parameters and time (mixed mode
repeated measures ANOVA, p = 0.048), indicating that the stimulation parameters
contributed to the change in LF/HF ratio. Further analysis of the H-tVNS group alone
revealed a significant decrease in LF/HF ratio (repeated measures ANOVA, time effect, p =
0.026; Supplementary Figure 1) whereas there was no significant change in LF/H ratio in L-
tVNS and sham groups. The percentage of those who responded to tVNS with a decrease in
LF/HF ratio was 67 % in the H-tVNS group compared to 49 % in the L-tVNS group. These
results indicate that H-tVNS is more effective in altering HRV in healthy participants.
0.4
0.6
0.8
1
1.2
1.4
1.6
Baseline Stimulation Recovery
LF
/H
F
H-tVNS
L-tVNS
Sham
*
Supplementary Figure 1 Comparison of
high pulse width and frequency tVNS and
low pulse width and frequency tVNS on
HRV. There is a significant decrease in
LF/HF ratio during H-tVNS (n=34;
p=0.026) whereas L-tVNS (n=63) has no
significant effect. There is a significant
difference in LF/HF ratio response
between H-tVNS and L-tVNS group
(p=0.048).
34
Supplementary Figure 2: Methods of blood pressure measurement. There is a
significant increase in systolic and mean BP during tVNS and recovery (p < 0.0005)
measured using a Finometer which is in place throughout the experiment. The Finometer
calibration system was used during experiment, however it was temporarily switched off
during recordings for 15 minutes. It is possible that this affected accurate BP monitoring. It
has also been reported that long term Finometer measurements may cause local oedema
affecting BP detection 2. To investigate this, BP was also measured from the arm using an
automatic BP machine. Three arm readings of BP were taken at baseline, during stimulation
and during recovery and the average of the readings compared to the Finometer
measurements. There was a significant difference between the mean and systolic BP results
measured using the 2 methods during tVNS and the recovery period (mixed mode repeated
measures ANOVA; *p = 0.023 and **p = 0.004 respectively). There was no significant
difference in diastolic BP measurements. Systolic and mean BP measured using the
Finometer increase during tVNS and recovery compared to arm BP measurements which
remain stable.
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Supplementary Figure 3 Individual HRV responses in participants who received
microneurography. LF/HF ratio decreased in 8 participants during tVNS and this
corresponded with a decrease in MSNA. LF/HF ratio increased in 2 participants who showed
no change in MSNA during tVNS.
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